Novel Stem Cell Memory CAR T Therapy Achieves Cancer Remission Without Preparatory Chemotherapy

New Cell study shows stem cell memory CAR T cells achieve remission at low doses without chemotherapy preconditioning, offering a safer path for cancer treatment.

By: AXL Media

Published: May 1, 2026, 9:01 AM EDT

Source: Information for this report was sourced from EurekAlert!

Engineering a Persistent Guard Against Hematologic Malignancies

Standard CAR T-cell treatments often struggle with durability, as the infused cells frequently fail to expand or survive long enough to provide a lasting cure. To overcome this limitation, researchers led by the Leibniz Institute for Immunotherapy focused on a specific subset of immune cells known as stem cell memory T cells, or TSCM. According to the study published on April 30, these cells possess a superior capacity for self-renewal and proliferation compared to the heterogeneous mixtures used in current therapies. By creating a clinical-grade platform for these cells, the team has successfully demonstrated a method to stabilize the cellular response against leukemia in a clinical setting.

Achieving Complete Remission Without Toxic Preconditioning

One of the most significant breakthroughs of this Phase 1 trial was the ability to achieve complete responses in patients without using lymphodepleting chemotherapy. Typically, patients must undergo intense chemical treatment to clear existing immune cells and make room for the CAR T infusion. However, Dr. James Kochenderfer of the National Cancer Institute noted that the TSCM platform yielded higher CAR T-cell levels on a per-cell basis, allowing for effective engraftment at doses as low as 250,000 cells per kilogram. This development could fundamentally change the patient experience by removing the side effects and risks associated with pre-infusion chemotherapy protocols.

Decoupling Therapeutic Expansion from Severe Inflammatory Toxicity

The trial results suggest a unique safety advantage, specifically regarding the reduction of cytokine-release syndrome, a common and dangerous inflammatory reaction. While high levels of T-cell expansion usually correlate with severe illness, the TSCM-treated patients experienced only mild side effects even when expansion reached levels that would normally trigger a crisis. Prof. Luca Gattinoni, the study’s first author, suggests that this specific cell product might separate the beneficial effects of immune expansion from its toxic consequences. This favorable tolerability profile makes the treatment a viable option for a broader range of patients, including those too frail for conventional high-dose regimens.